KYMERA THERAPEUTICS, INC. Interest Income, Other
KYMERA THERAPEUTICS, INC. (KYMR) reported Interest Income, Other of $14.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. interest income, other for the quarter ending 2026-06-30 was $14.48M, a 79.82% increase year-over-year.
- KYMERA THERAPEUTICS, INC. interest income, other for the quarter ending 2026-03-31 was $14.98M, a 68.00% increase year-over-year.
- KYMERA THERAPEUTICS, INC. interest income, other for the quarter ending 2025-12-31 was $11.01M, a 9.37% increase year-over-year.
- KYMERA THERAPEUTICS, INC. interest income, other for the quarter ending 2025-09-30 was $10.44M, a 7.70% increase year-over-year.
- KYMERA THERAPEUTICS, INC. interest income, other for fiscal 2025 was $38.42M, a 1.03% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. interest income, other for fiscal 2024 was $38.03M, a 102.65% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. interest income, other for fiscal 2023 was $18.76M, a 183.27% increase from fiscal 2022.
- KYMERA THERAPEUTICS, INC. interest income, other for fiscal 2022 was $6.62M.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.48M 10-Q · filed 2026-08-05 | $29.46M 10-Q · filed 2026-08-05 | $40.46M derived: sum of 3 quarters · filed 2026-08-05 | $50.91M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $14.98M 10-Q · filed 2026-04-30 | $25.99M derived: sum of 2 quarters · filed 2026-04-30 | $36.43M derived: sum of 3 quarters · filed 2026-04-30 | $44.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $21.45M derived: sum of 2 quarters · filed 2026-02-26 | $29.50M derived: sum of 3 quarters · filed 2026-08-05 | $38.42M 10-K · filed 2026-02-26 |
| 2025-09-30 | $10.44M 10-Q · filed 2025-11-04 | $18.50M derived: sum of 2 quarters · filed 2026-08-05 | $27.41M 10-Q · filed 2025-11-04 | $37.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $8.05M 10-Q · filed 2026-08-05 | $16.97M 10-Q · filed 2026-08-05 | $27.03M derived: sum of 3 quarters · filed 2026-08-05 | $36.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.92M 10-Q · filed 2026-04-30 | $18.98M derived: sum of 2 quarters · filed 2026-04-30 | $28.68M derived: sum of 3 quarters · filed 2026-04-30 | $37.60M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.76M derived: sum of 2 quarters · filed 2026-02-26 | $28.68M derived: sum of 3 quarters · filed 2026-02-26 | $38.03M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.70M 10-Q · filed 2025-11-04 | $18.62M derived: sum of 2 quarters · filed 2025-11-04 | $27.96M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $8.92M 10-Q · filed 2025-08-11 | $18.27M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $9.34M 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $18.76M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $6.62M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |